EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Management of Antithrombotic Therapy in Patients With Coexisting Atrial Fibrillation and Coronary Artery Disease Who Underwent Percutaneous Coronary Intervention Within the Last Year

Sebastian König iD, Sven Hohenstein, Johannes Leiner, Anne Nitsche, Alexander Staudt, Frank Steinborn, Christian Bietau, Henning T Baberg, Michael Niehaus, Jürgen Tebbenjohanns, Melchior Seyfarth, Markus W Ferrari und 4 weitere

Clinical Cardiology · 2025

DOI: 10.1002/clc.70196 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Cardiology, 2025. Verfasst von Sebastian König und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Coronary Artery Disease, Percutaneous Coronary Intervention, Fibrinolytic Agents. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was financially supported by Pfizer Pharma GmbH (Friedrichstr. 110, 10117 Berlin, Germany) under the study identifier 75906489..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronary artery disease (CAD) is a common comorbidity in patients with atrial fibrillation (AF), and optimal antithrombotic medication improves clinical outcomes in this high‐risk population. The aim of our study was to describe antithrombotic drug regimens in different patient cohorts.

Methods

We investigated data from the prospective Helios Heart registry (H2) and the Heart Center Leipzig routine clinical database (HZL). We included inpatient cases with AF and CAD (hospitalized from March 2021 to July 2024 [H2] or January 2017 to December 2021 [HZL]), who underwent percutaneous coronary intervention (PCI) within the last 12 months. Information on clinical characteristics, coronary interventions, and medication prescribed was obtained from electronic case report forms and/or administrative data based on ICD‐10, OPS, and ATC codes.

Results

We included 3481 (HZL), and 205 (H2) index cases with comparable baseline characteristics. Overall, 92.5% (HZL) and 87.6% (H2) of patients were on any anticoagulation, and 93.0% (HZL) and 80.2% (H2) were prescribed ≥ 1 antiplatelet agent. There were relevant differences in antithrombotic therapy when stratifying for PCI timing. Factors associated with higher (older age) or lower (comorbidity burden, antiplatelet treatment, prior left atrial appendage occlusion) prescription rates of OAC were identified. OAC therapy without adjunctive antiplatelet therapy was associated with an increased rate of rehospitalization for major adverse cardiovascular events at 12 months (HZL).

Conclusion

We presented current data on antithrombotic drug utilization in patients with AF and CAD and found comorbidity burden, concomitant antiplatelet treatment and other factors to be associated with lower anticoagulant prescription rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCoronary Artery DiseasePercutaneous Coronary InterventionFibrinolytic AgentsHumansFemaleMaleAgedRegistriesMiddle AgedTime FactorsRisk FactorsComorbidityTreatment OutcomePlatelet Aggregation InhibitorsFollow-Up StudiesGermanyProspective Studies

Stichwörter der Autor:innen

anticoagulationantithrombotic treatmentatrial fibrillationcoronary artery diseasepercutaneous coronary intervention

Substanzen

Fibrinolytic AgentsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.
  • Helios Health Institute, Clinical Trial Management & Real-World Data, Berlin, Germany.
  • Department of Cardiology and Angiology, Helios Hospital Schwerin, Schwerin, Germany.
  • Department of Cardiology/Interventional Electrophysiology, Helios Hospital Erfurt, Erfurt, Germany.
  • Department of Cardiology and Angiology, Helios Hospital Plauen, Plauen, Germany.
  • Department of Cardiology and Nephrology, Helios Hospital Berlin-Buch, Berlin, Germany.

ORCID-Profile: Sebastian König

Förderung

  • This study was financially supported by Pfizer Pharma GmbH (Friedrichstr. 110, 10117 Berlin, Germany) under the study identifier 75906489.

Zitieren

APA

König, S., Hohenstein, S., Leiner, J., Nitsche, A., Staudt, A., Steinborn, F., Bietau, C., Baberg, H. T., Niehaus, M., Tebbenjohanns, J., Seyfarth, M., Ferrari, M. W., Vorpahl, M. M., Kuhlen, R., Bode, K., & Bollmann, A. (2025). Management of Antithrombotic Therapy in Patients With Coexisting Atrial Fibrillation and Coronary Artery Disease Who Underwent Percutaneous Coronary Intervention Within the Last Year. Clinical Cardiology. https://doi.org/10.1002/clc.70196

Vancouver

König S, Hohenstein S, Leiner J, Nitsche A, Staudt A, Steinborn F, et al. Management of Antithrombotic Therapy in Patients With Coexisting Atrial Fibrillation and Coronary Artery Disease Who Underwent Percutaneous Coronary Intervention Within the Last Year. Clinical Cardiology. 2025. doi:10.1002/clc.70196

BibTeX
@article{Knig2025,
  author = {König, Sebastian and Hohenstein, Sven and Leiner, Johannes and Nitsche, Anne and Staudt, Alexander and Steinborn, Frank and Bietau, Christian and Baberg, Henning T and Niehaus, Michael and Tebbenjohanns, Jürgen and Seyfarth, Melchior and Ferrari, Markus W and Vorpahl, Marc M and Kuhlen, Ralf and Bode, Kerstin and Bollmann, Andreas},
  title = {Management of Antithrombotic Therapy in Patients With Coexisting Atrial Fibrillation and Coronary Artery Disease Who Underwent Percutaneous Coronary Intervention Within the Last Year},
  journal = {Clinical Cardiology},
  year = {2025},
  doi = {10.1002/clc.70196}
}
Kostenlos starten →